PPBT: purple-biotech.com Price/Earnings to Growth Multiple
Purple Biotech is developing a unique system to combat tumor resistance via the CM24 antibody. However, regional conflicts are disrupting logistics and threatening assets, as evidenced by the growth-adjusted P/E, where the value remains at 0.00. Currently, Purple Biotech is independently developing its molecules, limiting its engagement to technical cooperation with contract manufacturing plants.
Metric breakdowns and analytics for Purple Biotech (PPBT)
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
Debt to Capital Purple Biotech|PPBT - Long-Term Debt to Equity|Current Liabilities to Equity purple-biotech.com|PPBT - Company Total Debt|Debts to Book Capitalization Purple Biotech Corp|PPBT - Company Long-Term Debt|Company Short-Term Loans and Borrowings Purple Biotech|Critical Liquidity Ratio purple-biotech.com
- company profitability and valuation multiples indicators:
PPBT - Company Net Income|Expected Profit Purple Biotech|PPBT - P/E Multiple|Projected Price to Earnings Ratio Kitov Pharma|PPBT - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Purple Biotech Corp|PPBT - Operating profit EBITDA|Earnings per share for the last twelve months Purple Biotech|PPBT - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months purple-biotech.com|PPBT - Earnings per share growth in current year|Expected net earnings per share growth next year Purple Biotech
Summary company analytics:PPBT Purple Biotech Ltd
Market expectations for Purple Biotech (PPBT) are often inflated due to the complexity of its proprietary developments in the fight against solid tumors. By analyzing this growth stock attractiveness indicator on GURU.Markets, an investor compares the P/E ratio with earnings growth rates: a value below one signals that the asset is undervalued relative to its potential, which is critically important for the capital-intensive biopharmaceutical sector.
Competitors of Purple Biotech
ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen Pharma (URGN) - Price/Earnings to Growth Ratio|Bicara Therapeutics Inc - Growth-Adjusted Payback Ratio|PSNL (Personalis Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca Oncology ERAS|Price/Earnings to Growth Ratio Delcath Systems, Inc. (DCTH)|YMAB: Market Cap to Earnings and Growth Ratio|Aura Biosciences - Price/Earnings to Growth Multiple|PEG Multiple Candel Therapeutics Inc. CADL|ARAY - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio SLS (SELLAS Life Sciences)|Actuate Therapeutics, Inc. (ACTU) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio CTOR (citiusonc.com)|Price/Earnings to Growth Ratio TuHURA Biosciences Inc.|Price/Earnings to Growth Ratio TARA|PEG Multiple FATE|WHWK - Price to Earnings Adjusted for Growth Rate|TScan Therapeutics, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio CSBR|XBiotech USA - PEG Multiple|CVM: Price/Earnings to Growth Ratio|OSTX: PEG Multiple|RADX - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Artiva Biotherapeutics Inc.|Price to Earnings Adjusted for Growth Rate Adlai Nortye Limited ANL|Price/Earnings to Growth Multiple VERU (Veru)|Company Value to Earnings Growth Ratio TPST|PEG Multiple XLO (Xilio Therapeutics)|Renovaro Biosciences (RENB) - Price to Earnings Adjusted for Growth Rate|Mural Bio - PEG Multiple|Kairos Pharma Ltd (KAPA) - Price/Earnings to Growth Multiple|OKUR: PEG Multiple|CytoMed Therapeutics Limited - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Curis Inc.|Apollomics Corp - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio Tharimmune, Inc. (THAR)|ADVB: Market Cap to Earnings and Growth Ratio|PEG Multiple GNPX (Genprex)|Calidi Biotherapeutics Inc. - Price/Earnings to Growth Ratio|SBFM: Price/Earnings to Growth Multiple|Xenetic Biosciences - Company Value to Earnings Growth Ratio|SLRX: PEG Multiple|Price/Earnings to Growth Multiple American Oncology Network, Inc.|BGNE (BeiGene) - PEG Multiple|PEG Multiple Checkpoint Therapeutics Inc.|Price/Earnings to Growth Ratio Elevation Oncology, Inc. (ELEV)|icadmed.com - Growth-Adjusted P/E Ratio|PEG Multiple IKNA (Ikena Oncology)|NTBL - Price/Earnings to Growth Multiple|Viracta - PEG Multiple|Price to Earnings Adjusted for Growth Rate MorphoSys Inc|NAYA Bio (NAYA) - Price/Earnings to Growth Ratio|Ascentage - Growth-Adjusted Payback Ratio
